Login to Your Account



Clinic Roundup


Monday, May 7, 2012

• TapImmune Inc., of Seattle, said the Mayo Clinic received investigational new drug application allowance for a Phase I trial of the company's HER-2/neu vaccine in breast cancer patients who finished standard Herceptin (trastuzumab, Roche AG)-based therapy and are at high risk of disease recurrence. The primary endpoints will be safety and immunogenicity. TapImmune is sponsoring the study and has an exclusive option to license the antigen technology at the end of Phase I.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription